ARDELYX INC (ARDX) competitors & alternatives
Health Care · NASDAQ
ARDELYX INC (ARDX)'s top competitors and alternatives — its most similar public companies — include IRONWOOD PHARMA INC CLASS A (IRWD), PHATHOM PHARMACEUTICALS INC (PHAT), UNICYCIVE THERAPEUTICS INC (UNCY), AURINIA PHARMACEUTICALS INC (AUPH), DaVita (DVA), AKEBIA THERAPEUTICS INC (AKBA), PROKIDNEY CORP CLASS A (PROK), Jazz Pharmaceuticals (JAZZ), CATALYST PHARMACEUTICALS INC (CPRX), MANNKIND CORP (MNKD), Immunic, Inc. (IMUX) and TRAVERE THERAPEUTICS INC (TVTX). These are ARDELYX INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top ARDX competitors & alternatives
-
IRONWOOD PHARMA INC CLASS AIRWDHealth Care
Ironwood Pharmaceuticals is a GI-focused biotech company that generates stable profits from its blockbuster IBS-C therapy, LINZESS, while developing a pipeline…
$3.88 (as of 2026-07-22) · market cap $637M
-
PHATHOM PHARMACEUTICALS INCPHATHealth Care
Phathom is a commercial-stage biopharmaceutical company commercializing VOQUEZNA, the first US-approved potassium-competitive acid blocker (PCAB) for…
$11.70 (as of 2026-07-22) · market cap $933M
-
UNICYCIVE THERAPEUTICS INCUNCYHealth Care
A clinical-stage biotechnology firm developing nanoparticle-based and novel therapies to address significant unmet medical needs in kidney disease.
$5.57 (as of 2026-07-22) · market cap $149M
-
AURINIA PHARMACEUTICALS INCAUPHHealth Care
Aurinia is a specialty pharma company commercializing LUPKYNIS, the first oral calcineurin inhibitor approved for lupus nephritis, with strong profitability…
$15.33 (as of 2026-07-22) · market cap $2.0B
-
DaVitaDVAHealth Care
Leading US dialysis and integrated kidney care provider serving end-stage renal disease patients across clinical centers, home-based settings, and transplant…
$232.08 (as of 2026-07-22) · market cap $15.0B
-
AKEBIA THERAPEUTICS INCAKBAHealth Care
A biopharmaceutical company specialized in kidney disease therapeutics with a commercial portfolio for anemia and mineral metabolism and a pipeline of rare…
$1.26 (as of 2026-07-22) · market cap $349M
-
PROKIDNEY CORP CLASS APROKHealth Care
ProKidney is pioneering a first-in-class autologous kidney cell therapy to slow kidney function decline in advanced CKD and diabetes patients, currently in…
$1.53 (as of 2026-07-22) · market cap $462M
-
Jazz PharmaceuticalsJAZZHealth Care
A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of…
$250.41 (as of 2026-07-22) · market cap $16.0B
-
CATALYST PHARMACEUTICALS INCCPRXHealth Care
Catalyst Pharma commercializes rare disease therapies with a focus on neuromuscular and neuromuscular-inflammation disorders, generating strong cash flow from…
$31.49 (as of 2026-07-21) · market cap $3.9B
-
MANNKIND CORPMNKDHealth Care
MannKind is a biopharmaceutical company specializing in drug-device combinations, including inhaled therapies and on-body infusors, to treat cardiometabolic…
$3.84 (as of 2026-07-22) · market cap $1.2B
-
Immunic, Inc.IMUXHealth Care
Immunic is a late-stage biotech developing oral small-molecule therapies for multiple sclerosis and gastrointestinal diseases with Phase 3 data expected in…
$15.11 (as of 2026-07-22) · market cap $206M
-
TRAVERE THERAPEUTICS INCTVTXHealth Care
Rare kidney disease specialist with two approved FILSPARI formulations (IgAN, FSGS) and a clinical-stage enzyme therapy poised to become the first…
$56.26 (as of 2026-07-22) · market cap $5.2B
Not quite? Describe exactly what you want →
Peers are ARDELYX INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: ARDELYX INC (ARDX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.